{"id":32792,"date":"2022-06-01T23:14:04","date_gmt":"2022-06-01T23:14:04","guid":{"rendered":"https:\/\/harchi90.com\/bay-area-genomics-startup-emerges-from-stealth-with-600m-in-the-bank-and-promising-a-100-genome-test-endpoints-news\/"},"modified":"2022-06-01T23:14:04","modified_gmt":"2022-06-01T23:14:04","slug":"bay-area-genomics-startup-emerges-from-stealth-with-600m-in-the-bank-and-promising-a-100-genome-test-endpoints-news","status":"publish","type":"post","link":"https:\/\/harchi90.com\/bay-area-genomics-startup-emerges-from-stealth-with-600m-in-the-bank-and-promising-a-100-genome-test-endpoints-news\/","title":{"rendered":"Bay Area genomics startup emerges from stealth with $ 600M in the bank and promising a ‘$ 100 genome’ test – Endpoints News"},"content":{"rendered":"
\n

Count GSK in for the pneumococcal vaccine race.<\/p>\n

The British pharma is wagering $ 2.1 billion in cash – plus up to $ 1.2 billion in milestones – to buy out Affinivax and its 24-valent pneumococcal vaccine candidate, now in Phase II, as well as the technology that gave birth to the shot.<\/p>\n

“The proposed acquisition further strengthens our vaccines R&D pipeline, provides access to a new, potentially disruptive technology, and broadens GSK’s existing scientific footprint in the Boston area,” said outgoing R&D chief Hal Barron, who’s leaving in August to run the cell rejuvenation startup Altos Labs.<\/p>\n

\n <\/p>\n

Keep reading Endpoints with a free subscription<\/h3>\n

Unlock this story instantly and join 143,000+ biopharma pros reading Endpoints daily – and it’s free. <\/p>\n

\n